Section Arrow
LQDA.NASDAQ
- Liquidia Corp
Quotes are at least 15-min delayed:2026/11/14 14:46 EST
Regular Hours
Last
 57.41
-0.71 (-1.22%)
Day High 
59.5 
Prev. Close
58.12 
1-M High
58.74 
Volume 
1.93M 
Bid
56.8
Ask
57
Day Low
57 
Open
58.37 
1-M Low
26.13 
Market Cap 
5.24B 
Currency 美元 
P/E 36.47 
%Yield -- 
10-SMA 47.8 
20-SMA 44.2 
50-SMA 49.19 
52-W High 93.61 
52-W Low 22.31 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.05/4.00
Enterprise Value
5.38B
Balance Sheet
Book Value Per Share
-0.28
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
158.32M
Operating Revenue Per Share
0.20
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AKANAkanda Corp.1.36+0.6883+102.47%-- 
HLNHaleon plc9.17+0.08+0.88%18.97PE
HIMSHims & Hers Health19.73------ 
TEVATeva Pharmaceutical Industries Limited44.5+0.85+1.95%102.3PE
VTRSViatris20.82+0.15+0.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.